PUBLIC COMPANY
save$MIRMMirum Pharmaceuticals, Inc.
$MIRM96.13+0.65%Foster City, CA, USupdated 30m ago
community read0 votes
pipeline
6
marketed
3
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(6)
pipeline depth6 products
2Phase 21Phase 33Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- —Expanded-Access Program for the Treatment of Chronic Hepatitis D With Brelovitug
- phase3Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
- —Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
- phase2Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
- phase2MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)
- phase2A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
- —The REPLACE Registry for Cholbam® (Cholic Acid)
- phase2A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
🐶 Hiring Signal
News
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.biospace · 10d ago
- Vir's hepatitis delta combo tamps down virus as Gilead showdown loomsVir Biotechnology is targeting a mid-2027 regulatory submission for its monthly chronic hepatitis delta regimen, with head-to-head data against Gilead’s Hepcludex expected next quarter.biospace · 11d ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that